Sharma Rohan, Nalleballe Krishna, Shah Vishank, Haldal Shilpa, Spradley Thomas, Hasan Lana, Mylavarapu Krishna, Vyas Keyur, Kumar Manoj, Onteddu Sanjeeva, Gokden Murat, Kapoor Nidhi
Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Department of Neurology, John Hopkins University, Baltimore, MD 21205, USA.
Diagnostics (Basel). 2022 Apr 7;12(4):924. doi: 10.3390/diagnostics12040924.
Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is an ongoing pandemic that has affected over 400 million people worldwide and caused nearly 6 million deaths. Hemorrhagic encephalitis is an uncommon but serious complication of COVID-19. The etiology of this disease is multifactorial, including secondary to severe hypoxemia, systemic inflammation, direct viral invasion, hypercoagulability, etc. The clinical spectrum of COVID-19-related hemorrhagic encephalitis is also varied, ranging from leukoencephalopathy with microhemorrhage, acute necrotizing hemorrhagic encephalitis (ANHE) involving the cortex, basal ganglia, rarely brain stem and cervical spine, hemorrhagic posterior reversible encephalopathy syndrome (PRES) to superimposed co-infection with other organisms. We report a case series of three young patients with different presentations of hemorrhagic encephalitis after COVID-19 infection and a review of the literature. One patient had self-limiting ANHE in the setting of mild COVID-19 systemic illness. The second patient had self-limiting leukoencephalopathy with microhemorrhages in the setting of severe systemic diseases and ARDS, and clinically improved with the resolution of systemic illness. Both patients were healthy and did not have any premorbid conditions. The third patient with poorly controlled diabetes and hypertension had severe systemic illness with neurological involvement including multiple ischemic strokes, basal meningitis, hemorrhagic encephalitis with pathological evidence of cerebral mucormycosis, and Epstein-Barr virus coinfection, and improved after antifungal therapy.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发的疫情仍在持续,已影响全球超过4亿人,并导致近600万人死亡。出血性脑炎是新冠肺炎一种罕见但严重的并发症。该疾病的病因是多因素的,包括继发于严重低氧血症、全身炎症、病毒直接侵袭、高凝状态等。新冠肺炎相关出血性脑炎的临床谱也各不相同,从伴有微出血的白质脑病、累及皮质、基底神经节(很少累及脑干和颈椎)的急性坏死性出血性脑炎(ANHE)、出血性后部可逆性脑病综合征(PRES)到合并其他病原体的叠加感染。我们报告了一组3例新冠肺炎感染后出现不同表现的出血性脑炎年轻患者的病例系列,并对文献进行了综述。1例患者在轻度新冠肺炎全身疾病情况下发生自限性ANHE。第2例患者在严重全身疾病和急性呼吸窘迫综合征(ARDS)情况下发生自限性伴有微出血的白质脑病,随着全身疾病的缓解临床症状改善。这2例患者均健康,无任何基础疾病。第3例患有糖尿病和高血压且控制不佳的患者发生严重全身疾病并伴有神经受累,包括多发性缺血性中风、基底脑膜炎、具有脑毛霉菌病病理证据的出血性脑炎以及EB病毒合并感染,抗真菌治疗后病情改善。